Post Archive by Year

In 2023, 3.6 percent currently had post-COVID-19 condition and 2.3 percent had activity-limiting PCC

With about 20% of young adults infected with one of the herpes simplex viruses (HSV) in 2024, the World Health Organization (WHO) recently raised awareness of the related costs and vaccine candidate landscape.
On December 11, 2024, the WHO revealed that the Global Health Sector Strategy on HIV, viral hepatitis, and sexually transmitted infections for 2022-2030 highlighted the cost of genital herpes infections. The WHO reaffirmed that it is also working to advance research and develop new prevention tools, such as vaccines.

Since May 2022, non-endemic countries have reported mpox cases related to international and locally acquired patients from 127 countries/territories/areas.
Globally, from January 2022 through the end of November 2024, a total of 117,663 confirmed mpox cases, including 263 related fatalities, have been reported. This data indicates a Case Fatality Ratio of 0.2%. 
To clarify various outbreaks, the World Health Organization (WHO) announced today that it published the Mpox External Situation Report #44, highlighting Mpox virus (MPXV) subclade activity in all six WHO Regions.

Vaccines Europe recently conducted a pipeline review of its member companies, revealing numerous vaccine innovations in development, including candidates that will protect international travelers.
In today's interconnected world, international travel increases the risk of spreading infectious diseases. According to an analysis, between 42% and 79% of travelers to low—and middle-income countries become ill with a travel-associated disease.

Since 1998, various respiratory syncytial virus (RSV) monoclonal antibody (mAb) therapies have been approved to prevent serious lower respiratory tract disease caused by RSV in young children.
Over the past two years, a single-dose, long-acting mAb designed to protect infants has been approved in Canada, Europe, and the USA.
As of March 2024, among females with an infant less than 8 months, 41.3% reported that their infant received an approved mAbs.

As 2024 comes to a close, chikungunya virus (CHIKV) outbreaks have become prevalent in many tropical regions, particularly in Africa, South America, and Southeast Asia.
For the first time, the World Health Organization confirmed mosquito-transmitted CHIKV outbreaks have been identified in 115 countries, many located in the Region of the Americas.
As of December 19, 2024, the Pan American Health Organization reported over 421,000 CHIKV cases and 211 related fatalities in the Americas this year. 

Throughout the current (7th) cholera epidemic, considered to have started in 1961, access to vaccines has been essential. Over recent months, oral cholera vaccine (OCV) supply has been essentially depleted, leading to additional cholera outbreaks.
As of December 18, 2024, the World Health Organization (WHO) reported the OCV shortage may be ending, but over the past month, cholera outbreaks have remained severe in many countries.

With over 12.7 million dengue virus cases and 7,828 related fatalities in 2024, countries throughout the Region of the Americas are seeking access to innovative vaccines.
The United States is one of those countries needing a dengue vaccine.